A Pilot Study on the Effect of CYP2C19 Activity on Clopidogrel Resistance
Study on the Efficacy of an Investigational Treatment for Migraine
Not Recruiting
21 years - 100 years
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Heart Disease
Age:
21 years - 100 years
Gender: All
Who can participate: Participants aged 18-65 who have a clinical diagnosis of migraine and experience at least four migraine attacks per month are eligible. Individuals must not have any significant health conditions that could interfere with the study outcomes.
Study details: Participants will be randomly assigned to receive either the investigational treatment or a placebo. They will be required to take the assigned medication daily and maintain a headache diary to track the frequency and intensity of migraine attacks. A placebo is an inactive substance designed to mimic the investigational treatment without therapeutic effects.
Updated on
19 Feb 2024.
Study ID: 1011003112 (0609-28)
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
